| Trial ID: | L5018 |
| Source ID: | NCT00086502
|
| Associated Drug: |
Comparator: Sitagliptin
|
| Title: |
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00086502/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Comparator: Sitagliptin|DRUG: Comparator: Placebo|DRUG: Comparator: Pioglitazone|DRUG: Metformin
|
| Outcome Measures: |
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24, HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent., Baseline and week 24 | Secondary: Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24, Change from baseline at Week 24 is defined as Week 24 minus Week 0., Baseline and week 24
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
353
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2004-06
|
| Completion Date: |
2005-11
|
| Results First Posted: |
2010-04-19
|
| Last Update Posted: |
2016-02-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00086502
|
